Valiant Laboratories Ltd

Valiant Laboratories Ltd’s shares plunged to a fresh 52-week low of Rs.50 on 4 March 2026, marking a significant decline amid persistent underperformance and weak financial metrics. The stock’s fall reflects ongoing pressures within the Pharmaceuticals & Biotechnology sector, with the company’s valuation and profitability indicators signalling challenges in the near term.

Valiant Laboratories Ltd has touched a new 52-week low of Rs.50 today, marking a significant decline in its share price amid persistent downward momentum. The stock’s performance continues to lag behind its sector and broader market indices, reflecting ongoing pressures on the company’s financial and operational metrics.

Valiant Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has recorded a new all-time low of Rs.50, marking a significant downturn in its stock performance. The steep decline reflects ongoing difficulties faced by the company, with its shares underperforming both the sector and broader market indices over multiple time frames.

Valiant Laboratories Ltd has reached a new 52-week low of Rs.55, marking a significant decline in its stock price amid ongoing underperformance relative to its sector and benchmark indices. The stock’s recent trajectory reflects a series of financial and market pressures that have weighed on investor sentiment and valuation metrics.

Valiant Laboratories Ltd has reached a new 52-week low, with its share price touching an intraday low of ₹56.5, marking a significant decline amid ongoing pressures in the Pharmaceuticals & Biotechnology sector. The stock closed just 1.95% above its 52-week low of ₹55.85, reflecting sustained weakness over the past year.

Valiant Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 27 February 2026, providing investors with the latest perspective on the company’s position.

Valiant Laboratories Ltd has touched a new 52-week low of Rs.55.85 today, marking a significant decline in its stock price amid broader market gains. This fresh low reflects ongoing pressures on the pharmaceutical company’s financial performance and valuation metrics.

Valiant Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reached a new all-time low price of Rs. 55.85, marking a significant milestone in its ongoing decline. The stock’s recent performance continues to trail both its sector and broader market indices, reflecting persistent pressures on the company’s financial and market standing.

Valiant Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Valiant Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹367.00 crores, reported deeply concerning results for Q2 FY26, with net profit plunging 89.01% quarter-on-quarter to ₹0.20 crores from ₹1.82 crores in Q1 FY26. The sharp deterioration in profitability occurred despite revenue remaining relatively stable at ₹46.20 crores, down marginally by 1.32% from the previous quarter. The stock has reacted negatively to mounting operational challenges, declining 32.26% over the past year and trading at ₹67.27 as of February 11, 2026.

Valiant Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 February 2026, providing investors with the latest insights into its performance and outlook.

Valiant Laboratories Ltd has reached a new 52-week low, closing at Rs 56.48 on 29 Jan 2026, marking a significant decline amid broader market gains. The stock’s recent performance reflects ongoing pressures within the Pharmaceuticals & Biotechnology sector, with the share price now trading well below all key moving averages.

Shares of Valiant Laboratories Ltd have declined to an all-time low, reflecting a sustained period of underperformance relative to the broader market and sector benchmarks. The pharmaceutical and biotechnology company’s stock closed near its 52-week low, underscoring the severity of its current valuation and financial position.

Valiant Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has recorded a new 52-week low of Rs.57.02, marking a significant decline in its stock price amid broader market gains. This drop reflects ongoing concerns about the company’s financial health and valuation metrics despite recent sales and profit growth.

Valiant Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low of Rs.57.8 today, marking a significant decline in its share price amid a challenging market environment and subdued long-term fundamentals.